Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure - Trial NCT05613140
Access comprehensive clinical trial information for NCT05613140 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Completed. The study focuses on Chronic Heart Failure. Target enrollment is 9230 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Aug 02, 2021
Nov 05, 2021
Primary Outcome
Mean number of Heart Failure - specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Summary
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care
 within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially
 insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure
 with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart
 failure (CHF) (cohort 2).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05613140
Non-Device Trial